Washington University School of Medicine, St Louis, MO.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):296-302. doi: 10.1182/hematology.2021000262.
Immunotherapy is now a well-established modality in the treatment of cancer. Although several platforms to redirect the immune response exist, the use of genetically modified T cells has garnered particular attention in recent years. This is due, in large part, to their success in the treatment of B-cell malignancies. Adoptively transferred T cells have also demonstrated efficacy in the treatment of systemic viral infections that occur following hematopoietic cell transplantation prior to immune reconstitution. Here we discuss the techniques that enable redirection of T lymphocytes to treat cancer or infection and the current indications for these therapies.
免疫疗法现已成为癌症治疗的一种成熟手段。虽然存在几种可重新定向免疫反应的平台，但近年来，基因修饰 T 细胞的应用受到了特别关注。这在很大程度上是因为它们在治疗 B 细胞恶性肿瘤方面取得了成功。过继转移的 T 细胞在免疫重建前造血细胞移植后发生全身性病毒感染的治疗中也显示出疗效。本文我们将讨论可使 T 淋巴细胞转向治疗癌症或感染的技术，以及这些疗法的现有适应证。
